Wendy A. Teft

1.7k total citations
38 papers, 1.3k citations indexed

About

Wendy A. Teft is a scholar working on Oncology, Genetics and Pharmacology. According to data from OpenAlex, Wendy A. Teft has authored 38 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 15 papers in Genetics and 9 papers in Pharmacology. Recurrent topics in Wendy A. Teft's work include Pharmacogenetics and Drug Metabolism (8 papers), Drug Transport and Resistance Mechanisms (8 papers) and Estrogen and related hormone effects (7 papers). Wendy A. Teft is often cited by papers focused on Pharmacogenetics and Drug Metabolism (8 papers), Drug Transport and Resistance Mechanisms (8 papers) and Estrogen and related hormone effects (7 papers). Wendy A. Teft collaborates with scholars based in Canada, United States and Belgium. Wendy A. Teft's co-authors include Joaquı́n Madrenas, Mark G. Kirchhof, Richard B. Kim, Yun‐Hee Choi, Aze Wilson, Rommel G. Tirona, Sara E. Mansell, Robert A. Hegele, Eric Winquist and Bridget L. Morse and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Annual Review of Immunology.

In The Last Decade

Wendy A. Teft

37 papers receiving 1.3k citations

Peers

Countries citing papers authored by Wendy A. Teft

Since Specialization

Citations

This map shows the geographic impact of Wendy A. Teft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wendy A. Teft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wendy A. Teft more than expected).

Fields of papers citing papers by Wendy A. Teft

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wendy A. Teft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wendy A. Teft. The network helps show where Wendy A. Teft may publish in the future.

Co-authorship network of co-authors of Wendy A. Teft

This figure shows the co-authorship network connecting the top 25 collaborators of Wendy A. Teft. A scholar is included among the top collaborators of Wendy A. Teft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wendy A. Teft. Wendy A. Teft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Metabolism and response to stress gene signatures reveal ulcerative colitis heterogeneity and identify patients with increased response to therapy 2025 ·Journal of Crohn s and Colitis ·Bryan Linggi, (unknown), Bruno Sangiorgi, Michelle I. Smith, Wendy A. Teft, Vipul Jairath, Christopher Ma, Niels Vande Casteele	0
2	Effect of storage time on peripheral blood mononuclear cell isolation from blood collected in vacutainer CPT™ tubes 2023 ·Journal of Immunological Methods ·Bryan Linggi, Jonathan Cremer, Zhongya Wang, (unknown), Séverine Vermeire, Pavine Lefèvre, Lisa M. Shackelton, Vipul Jairath, Wendy A. Teft, Niels Vande Casteele, Bram Verstockt	3
3	Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohn’s disease 2020 ·Scientific Reports ·Aze Wilson, (unknown), Wendy A. Teft, Richard B. Kim	53
4	Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients 2020 ·Breast Cancer Research and Treatment ·Adrienne E. Borrie, (unknown), Yun‐Hee Choi, Francisco Perera, Nancy Read, Tracy Sexton, Michael Lock, Theodore A. Vandenberg, Karin Hahn, Jawaid Younus, Diane Logan, Kylea Potvin, Brian Yaremko, Edward Yu, John Lenehan, Stephen Welch, Wendy A. Teft, Richard B. Kim	11
5	Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients 2018 ·Oral Oncology ·Wendy A. Teft, Eric Winquist, Anthony C. Nichols, Sara Kuruvilla, Suzanne Richter, Christina Parker, P. Francis, (unknown), (unknown), Nedal Bukhari, Yun‐Hee Choi, Stephen Welch, David A. Palma, John Yoo, Richard B. Kim	30
6	Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer 2018 ·Breast Cancer Research and Treatment ·Adrienne E. Borrie, (unknown), Yun‐Hee Choi, Francisco Perera, Nancy Read, Tracy Sexton, Michael Lock, Theodore A. Vandenberg, Karin Hahn, Robert Dinniwell, Jawaid Younus, Diane Logan, Kylea Potvin, Brian Yaremko, Edward Yu, John Lenehan, Stephen Welch, Rachel F. Tyndale, Wendy A. Teft, Richard B. Kim	11
7	CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy 2018 ·Breast Cancer Research and Treatment ·(unknown), Wendy A. Teft, (unknown), Daniel J. Lizotte, Richard B. Kim	12
8	Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care 2017 ·Canadian Journal of Cardiology ·(unknown), Anthony Tang, Steven E. Gryn, Peter Leong‐Sit, Allan C. Skanes, Jeffrey Alfonsi, George K. Dresser, (unknown), (unknown), Daniel J. Lizotte, Wendy A. Teft, Ute I. Schwarz, Rommel G. Tirona, Richard B. Kim	49
9	Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report 2016 ·BMC Cancer ·(unknown), Wendy A. Teft, Richard B. Kim	8
10	Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance 2015 ·Molecular Cancer Therapeutics ·(unknown), Brenda F. Leake, Wendy A. Teft, Rommel G. Tirona, Richard B. Kim, Richard Ho	33
11	OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy 2015 ·British Journal of Cancer ·Wendy A. Teft, Stephen Welch, John Lenehan, Jeremy Parfitt, Yun‐Hee Choi, Eric Winquist, R B Kim	61
12	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease 2015 ·Digestive Diseases and Sciences ·Aze Wilson, Wendy A. Teft, Bridget L. Morse, Yun‐Hee Choi, Sarah Woolsey, Marianne K. DeGorter, Robert A. Hegele, Rommel G. Tirona, Richard B. Kim	77
13	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease 2015 ·The American Journal of Gastroenterology ·Aze Wilson, Wendy A. Teft, Rommel G. Tirona, Sarah Woolsey, Bridget L. Morse, Marianne K. DeGorter, Robert A. Hegele, Yun‐Hee Choi, Richard Kim	5
14	Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A422 2014 ·Breast Cancer Research and Treatment* ·(unknown), Wendy A. Teft, Yun‐Hee Choi, Eric Winquist, Richard B. Kim	30
15	Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts 2013 ·Breast Cancer Research and Treatment ·Inna Y. Gong, Wendy A. Teft, Justin Q. Ly, Yung‐Hsiang Chen, Bruno Alicke, Richard B. Kim, Edna F. Choo	28
16	CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy 2013 ·Breast Cancer Research and Treatment ·Wendy A. Teft, Inna Y. Gong, B. Dingle, Kylea Potvin, Jawaid Younus, Theodore A. Vandenberg, Muriel Brackstone, Francisco Perera, Yun‐Hee Choi, Guangyong Zou, (unknown), Rommel G. Tirona, Richard B. Kim	62
17	Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1) 2010 ·Drug Metabolism and Disposition ·Wendy A. Teft, Sara E. Mansell, Richard B. Kim	57
18	Structure-Function analysis of the CTLA-4 interaction with PP2A 2009 ·BMC Immunology ·Wendy A. Teft, Thu Chau, Joaquı́n Madrenas	21
19	Molecular Determinants of Inverse Agonist Activity of Biologicals Targeting CTLA-4 2007 ·The Journal of Immunology ·Wendy A. Teft, Joaquı́n Madrenas	7
20	Conversion of CTLA-4 from Inhibitor to Activator of T Cells with a Bispecific Tandem Single-Chain Fv Ligand 2004 ·The Journal of Immunology ·Joaquı́n Madrenas, Luan A. Chau, Wendy A. Teft, Paul W. Wu, Jason Jussif, Marion T. Kasaian, Beatriz M. Carreno, Vincent Ling	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact